SCHEMBL3519937

SCHEMBL3519937

O=C(O)c1c(O)c(Br)cc2nc(-c3cccs3)cnc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 3/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
PPARG P37231 2/20 0.47
PRNP P04156 1/20 0.47
NCOR2 Q9Y618 1/20 0.47
KDM4E B2RXH2 6/20 0.46
ALDH1A1 P00352 4/20 0.46
GAA P10253 4/20 0.46
RAB9A P51151 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
NPC1 O15118 2/20 0.46
HPGD P15428 2/20 0.46
CASP1 P29466 2/20 0.46
CASP7 P55210 2/20 0.46
HSD17B10 Q99714 2/20 0.46
MAPK10 P53779 1/20 0.46
TP53 P04637 3/20 0.40
GLA P06280 1/20 0.39
MAPT P10636 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3517411 0.88 KDM4E (0.48) RXFP1MEN1KMT2APPARGPRNP
SCHEMBL3755841 0.85 EGLN3 (0.46) RXFP1MEN1KMT2APPARGPRNP
SCHEMBL3521940 0.81 HPGD (0.41) MEN1KMT2AKDM4ERAB9AHPGD
SCHEMBL3519547 0.81 KDM4E (0.42) RXFP1MEN1KMT2APPARGPRNP
SCHEMBL3518154 0.79 RXFP1 (0.41) RXFP1MEN1KMT2APPARGPRNP
SCHEMBL3521337 0.77 MEN1 (0.47) RXFP1MEN1KMT2APPARGPRNP
SCHEMBL3521131 0.76 RXFP1 (0.40) RXFP1MEN1KMT2APPARGPRNP
SCHEMBL3523288 0.74 KMO (0.44) ALDH1A1GAAGRIN2B
SCHEMBL3518804 0.74 EGLN3 (0.52) MEN1KMT2AKDM4EALDH1A1GAA
SCHEMBL8504154 0.72 NPC1 (0.65) RXFP1MEN1KMT2APPARGPRNP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 RXFP1 1151/4885MEN1 2552/4885KMT2A 300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.